



中信建投证券股份有限公司
CHINA SECURITIES CO., LTD.

1.....	4
2.....	8
3.....	22
4.....	26
5.....	31
6.....	34
7.....	38
8.....	43
9.....	50
10.....	55
11.....	58

1

17.33

5

70%

15

30%

2025

9

30

6.18

2.81

1

26 --

26

2

26 --

26

1

2

1

2

2

26.74

162.23%

2025

2024

58,234.95

10%

18,013.61

14.39%


2024

2025

2024

2025


1



■

—


2024 -2030



	2025 1-7		2024		2023	
	19,016.63	83.55%	55,010.39	94.46%	65,289.07	100.00%
	3,745.45	16.45%	3,224.56	5.54%	0.08	0.00%
	22,762.09	100.00%	58,234.95	100.00%	65,289.15	100.00%


3 IGRA

IGRA



	2025	1-7	2024	2023
		583.33	1,000.00	1,000.00
		395.38	738.07	804.41

		162.23%



4

2025 8 26

mRNA

100%

8,318.38

1

mRNA

2

3


mRNA

mRNA

5

2025 2026 2027

"	"	16,593	18,584	20,814	
		55,991			77,500
2025	7		5,967.95		



2025

	2025	2025 E	2025 1-9	2025 1-7

2026 2027

	2027	2026

6

2023 3
5,000

1

2023

2025

4,321

5,000

1

2

1

2

1

2

7

2024

2024 2025 1-7

3,224.56

3,745.45

5.54% 16.45%

1

3

\approx	
\approx	

4

1 “ ”

2

3

2

1

2

1

		2024	2023

2

			2024	2023
		43.85%	41.05%	38.56%

	2025 1-7		2024		2023	
	1,067.19	100.00%	2,219.95	100.00%	2,924.42	100.00%

			2024	2023
		82.76%	84.60%	88.10%
		94.39%	95.96%	95.52%

10

2025 7 31

7,034.34

Xs02

TB-PPD

Xs02

TB-PPD

Xs02

BLA

GMP

11

" "

" "


		
		
		






(本页无正文，为《中信建投证券股份有限公司关于深圳证券交易所<关于对北京利德曼生化股份有限公司的重组问询函>回复之核查意见》之签字盖章页)


财务顾问主办人：



周圣哲



王瑀



田斌

中信建投证券股份有限公司



2026年10月9日